Back to top
more

Cencora, Inc. (COR)

(Real Time Quote from BATS)

$237.45 USD

237.45
360,084

-0.88 (-0.37%)

Updated Jun 26, 2024 02:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion

One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.

GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response

GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Medtronic's (MDT) MiniMed 780G System Study Data Favorable

Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend

Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.

Labcorp (LH) Introduces Weight Loss Management Portfolio

Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.

Abbott (ABT) to Reduce Childhood Malnutrition With New Pact

Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable

Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

DaVita (DVA) Expands Operational Footprint Via New Agreement

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.